文献速递糖尿病

免疫检查点抑制剂诱导糖尿病的临床与生化恢复伴GAD抗体血清转换

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.
PubMed 文献 · Diabetes Care · 2026-01-01

本文报告一例免疫检查点抑制剂诱导糖尿病(ICI-D)患者在接受英夫利西单抗治疗后,胰岛素需求逐步下降并最终停用胰岛素,GAD抗体约2个月内转阴,尿C肽/肌酐比值升高提示内源性胰岛素分泌恢复,提示ICI-D可能可逆。

要点

  • ICI-D患者在接受英夫利西单抗后胰岛素需求下降并可停用胰岛素。
  • GAD抗体在约2个月内转阴,尿C肽/肌酐比值升高提示内源性胰岛素分泌恢复。
  • 英夫利西单抗可能作为ICI-D的潜在疾病修饰治疗,需进一步研究。

核心结论

  • ICI-D患者可能出现临床与生化恢复,时间关联提示英夫利西单抗可能起了一定作用。

研究设计与样本

  • 个案报告:一例黑色素瘤患者接受伊匹木单抗联合纳武利尤单抗后改为纳武利尤单抗单药治疗。

主要发现

  • 患者出现突发症状性高血糖伴轻度酮症,GAD抗体和胰岛素自身抗体阳性,符合ICI-D。
  • 因ICI相关关节炎接受英夫利西单抗后,胰岛素需求逐步下降并最终停用胰岛素。
  • GAD抗体约2个月内转阴并 later 无法检出,尿C肽/肌酐比值随时间升高。

临床怎么用

  • ICI-D患者出现胰岛素需求下降时,可评估内源性胰岛素分泌恢复的可能性。

局限性

  • 为单个病例报告,英夫利西单抗的潜在作用仅为时间关联推测,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint inhibitors (ICIs) improve outcomes across multiple cancers but may cause immune-related adverse events, including ICI-induced diabetes (ICI-D). ICI-D typically presents abruptly with severe insulin deficiency, and published cases have largely described irreversible loss of endogenous insulin secretion. RESEARCH DESIGN AND METHODS: We report a novel case of clinical and biochemical recovery of ICI-D. RESULTS: Following melanoma treatment with ipilimumab plus nivolumab, then nivolumab monotherapy, the patient developed abrupt-onset symptomatic hyperglycemia with mild ketosis and positive GAD and insulin autoantibodies, consistent with ICI-D. The patient subsequently received infliximab for ICI-related arthritis. Insulin requirements progressively declined, allowing discontinuation of insulin therapy. GAD antibodies normalized within ∼2 months and later became undetectable. Urine C-peptide-to-creatinine ratios increased over time, consistent with endogenous insulin secretion. CONCLUSIONS: Recovery from ICI-D may occur. The temporal association suggests infliximab may have contributed, warranting further study as a potential disease-modifying therapy.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Chen LR, Cooksley T, Kochhar R, et al. Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies. Diabetes Care. 2026. PMID: 42384047. doi:10.2337/dc26-0700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。